Full Breakdown
WHO's New Policy on TB Testing: Expanding Access with Affordable NPOC Tests
3/26/2026, 11:14:54 PM
Introduction to WHO's Recommendations
On February 26, 2023, the World Health Organization (WHO) introduced a policy recommending the use of new, affordable near-point-of-care (NPOC) molecular tests for tuberculosis (TB) diagnosis. This policy aims to enhance access to TB testing by utilizing easy-to-collect tongue swab samples, particularly in high TB burden countries. The WHO emphasizes that these NPOC tests should be used as initial diagnostic tools for adults and adolescents showing symptoms of pulmonary TB, replacing the traditional sputum smear microscopy. However, the current NPOC tests are limited to detecting TB and do not assess drug resistance, raising questions about their comprehensive applicability.
Advantages of NPOC Tests
The WHO's shift towards NPOC tests marks a significant departure from existing national TB control strategies, which have often relied on expensive molecular tools deployed at higher healthcare levels. Historically, technologies like Xpert MTB/RIF have been imported, making them cost-prohibitive for low and middle-income countries. The introduction of affordable, locally manufactured NPOC tests is expected to decentralize TB testing to primary care settings, thereby expanding access. Additionally, the use of tongue swabs addresses the challenge faced by nearly a quarter of adults who cannot produce sputum samples, thus broadening the testing pool.
Implementation Strategies and Cost Considerations
The WHO's policy also includes a sputum pooling strategy, allowing samples from multiple individuals to be tested together when resources are constrained. This approach is particularly relevant for countries like India, where the cost of individual molecular tests can be prohibitive. The WHO has endorsed several NPOC tests, including the MTB Nucleic Acid Test Card by Pluslife Biotech and the UniAMP® Mycobacterium Tuberculosis Nucleic Acid Test Card by Huwel Lifesciences, both of which are designed for use with tongue swabs. The Pluslife test is available at approximately $3.60 per test, significantly lower than other WHO-recommended rapid molecular tests, potentially enabling countries to maximize their limited healthcare budgets.
Global Rollout and Future Directions
The Global Fund is collaborating with 13 high TB burden countries across the Americas, Africa, and Asia to implement NPOC-NAATs by 2026. To support this initiative, the WHO plans to release an updated operational handbook on tuberculosis, which will provide guidance on the integration of these new diagnostic technologies into national health programs. The WHO also aims to publish a toolkit specifically for near-point-of-care and swab-based TB testing.
Criticism and Challenges
Despite the advancements, some experts express concerns about the reliance on pooled testing in resource-constrained settings. They advocate for individual sample testing to ensure accurate diagnosis and treatment. The increased domestic budget for TB in India and the availability of ICMR-approved molecular tests offer hope for achieving universal molecular testing, but challenges remain in operationalizing the WHO's recommendations effectively.
Conclusion
The WHO's new policy on TB testing represents a pivotal step towards improving diagnostic access in high-burden countries. By promoting affordable NPOC tests and innovative sampling methods, the WHO aims to close the diagnostic gap in TB detection. However, successful implementation will require concerted efforts from governments and healthcare providers to adapt these recommendations into effective national TB control strategies.
Verbatim Quotes
- “when sputum cannot be obtained, NPOC-NAATs on tongue swabs should be used as initial diagnostic tests for TB.” — World Health Organization
- “I am hoping India can be more ambitious and make sure every individual sample is tested separately.” — Expert Commentator
Conflicting Reports & Gaps
There is ongoing debate regarding the effectiveness of pooled testing versus individual sample testing, with some experts advocating for the latter to ensure accurate diagnoses. Additionally, while the WHO's recommendations are clear, the practical steps for implementation in various national contexts remain to be fully defined.
